Tags

Type your tag names separated by a space and hit enter

Combined effect of a farnesoid X receptor agonist and dipeptidyl peptidase-4 inhibitor on hepatic fibrosis.
Hepatol Res 2019; 49(10):1147-1161HR

Abstract

AIM

Non-alcoholic steatohepatitis (NASH) has a broad clinicopathological spectrum (inflammation to severe fibrosis). The farnesoid X receptor agonist obeticholic acid (OCA) ameliorates the histological features of NASH; satisfactory antifibrotic effects have not yet been reported. Here, we investigated the combined effects of OCA + a dipeptidyl peptidase-4 inhibitor (sitagliptin) on hepatic fibrogenesis in a rat model of NASH.

METHODS

Fifty Fischer 344 rats were fed a choline-deficient L-amino-acid-defined (CDAA) diet for 12 weeks. The in vitro and in vivo effects of OCA + sitagliptin were assessed along with hepatic fibrogenesis, lipopolysaccharide-Toll-like receptor 4 (TLR4) regulatory cascade and intestinal barrier function. Direct inhibitory effects of OCA + sitagliptin on activated hepatic stellate cells (Ac-HSCs) were assessed in vitro.

RESULTS

Treatment with OCA + sitagliptin potentially inhibited hepatic fibrogenesis along with Ac-HSC proliferation and hepatic transforming growth factor (TGF)-β1, α1(I)-procollagen, and tissue inhibitor of metalloproteinase-1 (TIMP-1) mRNA expression and hydroxyproline levels. Obeticholic acid inhibited hepatic TLR4 expression and increased hepatic matrix metalloproteinase-2 expression. Obeticholic acid decreased intestinal permeability by ameliorating CDAA diet-induced zonula occludens-1 disruption, whereas sitagliptin directly inhibited Ac-HSC proliferation. The in vitro suppressive effects of OCA + sitagliptin on TGF-β1 and α1(I)-procollagen mRNA expression and p38 phosphorylation in Ac-HSCs were almost consistent. Sitagliptin directly inhibited the regulation of Ac-HSC.

CONCLUSIONS

Treatment with OCA + sitagliptin synergistically affected hepatic fibrogenesis by counteracting endotoxemia induced by intestinal barrier dysfunction and suppressing Ac-HSC proliferation. Thus, OCA + sitagliptin could be a promising therapeutic strategy for NASH.

Authors+Show Affiliations

Third Department of Internal Medicine, Nara Medical University, Kashihara, Nara, Japan.Third Department of Internal Medicine, Nara Medical University, Kashihara, Nara, Japan.Third Department of Internal Medicine, Nara Medical University, Kashihara, Nara, Japan.Third Department of Internal Medicine, Nara Medical University, Kashihara, Nara, Japan.Third Department of Internal Medicine, Nara Medical University, Kashihara, Nara, Japan.Third Department of Internal Medicine, Nara Medical University, Kashihara, Nara, Japan.Third Department of Internal Medicine, Nara Medical University, Kashihara, Nara, Japan.Third Department of Internal Medicine, Nara Medical University, Kashihara, Nara, Japan.Third Department of Internal Medicine, Nara Medical University, Kashihara, Nara, Japan.Third Department of Internal Medicine, Nara Medical University, Kashihara, Nara, Japan.Third Department of Internal Medicine, Nara Medical University, Kashihara, Nara, Japan.Third Department of Internal Medicine, Nara Medical University, Kashihara, Nara, Japan.Third Department of Internal Medicine, Nara Medical University, Kashihara, Nara, Japan.Third Department of Internal Medicine, Nara Medical University, Kashihara, Nara, Japan.Third Department of Internal Medicine, Nara Medical University, Kashihara, Nara, Japan.Third Department of Internal Medicine, Nara Medical University, Kashihara, Nara, Japan.Third Department of Internal Medicine, Nara Medical University, Kashihara, Nara, Japan.Third Department of Internal Medicine, Nara Medical University, Kashihara, Nara, Japan.Third Department of Internal Medicine, Nara Medical University, Kashihara, Nara, Japan.Third Department of Internal Medicine, Nara Medical University, Kashihara, Nara, Japan.Third Department of Internal Medicine, Nara Medical University, Kashihara, Nara, Japan.Third Department of Internal Medicine, Nara Medical University, Kashihara, Nara, Japan.Third Department of Internal Medicine, Nara Medical University, Kashihara, Nara, Japan.Third Department of Internal Medicine, Nara Medical University, Kashihara, Nara, Japan.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31177586

Citation

Shimozato, Naotaka, et al. "Combined Effect of a Farnesoid X Receptor Agonist and Dipeptidyl Peptidase-4 Inhibitor On Hepatic Fibrosis." Hepatology Research : the Official Journal of the Japan Society of Hepatology, vol. 49, no. 10, 2019, pp. 1147-1161.
Shimozato N, Namisaki T, Kaji K, et al. Combined effect of a farnesoid X receptor agonist and dipeptidyl peptidase-4 inhibitor on hepatic fibrosis. Hepatol Res. 2019;49(10):1147-1161.
Shimozato, N., Namisaki, T., Kaji, K., Kitade, M., Okura, Y., Sato, S., ... Yoshiji, H. (2019). Combined effect of a farnesoid X receptor agonist and dipeptidyl peptidase-4 inhibitor on hepatic fibrosis. Hepatology Research : the Official Journal of the Japan Society of Hepatology, 49(10), pp. 1147-1161. doi:10.1111/hepr.13385.
Shimozato N, et al. Combined Effect of a Farnesoid X Receptor Agonist and Dipeptidyl Peptidase-4 Inhibitor On Hepatic Fibrosis. Hepatol Res. 2019;49(10):1147-1161. PubMed PMID: 31177586.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Combined effect of a farnesoid X receptor agonist and dipeptidyl peptidase-4 inhibitor on hepatic fibrosis. AU - Shimozato,Naotaka, AU - Namisaki,Tadashi, AU - Kaji,Kosuke, AU - Kitade,Mitsuteru, AU - Okura,Yasushi, AU - Sato,Shinya, AU - Moriya,Kei, AU - Seki,Kenichiro, AU - Kawaratani,Hideto, AU - Takaya,Hiroaki, AU - Sawada,Yasuhiko, AU - Saikawa,Soichiro, AU - Nakanishi,Keisuke, AU - Furukawa,Masanori, AU - Fujinaga,Yukihisa, AU - Kubo,Takuya, AU - Asada,Kiyoshi, AU - Kitagawa,Koh, AU - Tsuji,Yuki, AU - Kaya,Daisuke, AU - Ozutsumi,Takahiro, AU - Akahane,Takemi, AU - Mitoro,Akira, AU - Yoshiji,Hitoshi, Y1 - 2019/07/15/ PY - 2018/12/28/received PY - 2019/05/18/revised PY - 2019/05/22/accepted PY - 2019/6/10/pubmed PY - 2019/6/10/medline PY - 2019/6/10/entrez KW - hepatic stellate cell KW - non-alcoholic steatohepatitis KW - obeticholic acid KW - sitagliptin SP - 1147 EP - 1161 JF - Hepatology research : the official journal of the Japan Society of Hepatology JO - Hepatol. Res. VL - 49 IS - 10 N2 - AIM: Non-alcoholic steatohepatitis (NASH) has a broad clinicopathological spectrum (inflammation to severe fibrosis). The farnesoid X receptor agonist obeticholic acid (OCA) ameliorates the histological features of NASH; satisfactory antifibrotic effects have not yet been reported. Here, we investigated the combined effects of OCA + a dipeptidyl peptidase-4 inhibitor (sitagliptin) on hepatic fibrogenesis in a rat model of NASH. METHODS: Fifty Fischer 344 rats were fed a choline-deficient L-amino-acid-defined (CDAA) diet for 12 weeks. The in vitro and in vivo effects of OCA + sitagliptin were assessed along with hepatic fibrogenesis, lipopolysaccharide-Toll-like receptor 4 (TLR4) regulatory cascade and intestinal barrier function. Direct inhibitory effects of OCA + sitagliptin on activated hepatic stellate cells (Ac-HSCs) were assessed in vitro. RESULTS: Treatment with OCA + sitagliptin potentially inhibited hepatic fibrogenesis along with Ac-HSC proliferation and hepatic transforming growth factor (TGF)-β1, α1(I)-procollagen, and tissue inhibitor of metalloproteinase-1 (TIMP-1) mRNA expression and hydroxyproline levels. Obeticholic acid inhibited hepatic TLR4 expression and increased hepatic matrix metalloproteinase-2 expression. Obeticholic acid decreased intestinal permeability by ameliorating CDAA diet-induced zonula occludens-1 disruption, whereas sitagliptin directly inhibited Ac-HSC proliferation. The in vitro suppressive effects of OCA + sitagliptin on TGF-β1 and α1(I)-procollagen mRNA expression and p38 phosphorylation in Ac-HSCs were almost consistent. Sitagliptin directly inhibited the regulation of Ac-HSC. CONCLUSIONS: Treatment with OCA + sitagliptin synergistically affected hepatic fibrogenesis by counteracting endotoxemia induced by intestinal barrier dysfunction and suppressing Ac-HSC proliferation. Thus, OCA + sitagliptin could be a promising therapeutic strategy for NASH. SN - 1386-6346 UR - https://www.unboundmedicine.com/medline/citation/31177586/The_combined_effect_of_a_farnesoid_X_receptor_agonist_and_dipeptidyl_peptidase-4_inhibitor_on_hepatic_fibrosis L2 - https://doi.org/10.1111/hepr.13385 DB - PRIME DP - Unbound Medicine ER -